ARQT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARQT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-26), Arcutis Biotherapeutics's share price is $9.16. Arcutis Biotherapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.69. Hence, Arcutis Biotherapeutics's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Arcutis Biotherapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:
Arcutis Biotherapeutics's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.29. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-2.69.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -4.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -40.80% per year.
During the past 7 years, Arcutis Biotherapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was -4.00% per year. The lowest was -147.70% per year. And the median was -63.20% per year.
The historical data trend for Arcutis Biotherapeutics's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcutis Biotherapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
Arcutis Biotherapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Arcutis Biotherapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Arcutis Biotherapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Arcutis Biotherapeutics's Price-to-Free-Cash-Flow falls into.
Arcutis Biotherapeutics's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 9.16 | / | -2.692 | |
= | N/A |
Arcutis Biotherapeutics's Share Price of today is $9.16.
Arcutis Biotherapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.69.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
Arcutis Biotherapeutics (NAS:ARQT) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of Arcutis Biotherapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Masaru Matsuda | officer: SVP and General Counsel | 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121 |
Frazier Life Sciences Viii, L.p. | 10 percent owner | 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Larry Todd Edwards | officer: Chief Commercial Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361 |
Patrick Burnett | officer: See Remarks | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Todd Franklin Watanabe | director, officer: President and CEO | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
Howard G. Welgus | director | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
Scott L Burrows | officer: Chief Financial Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361 |
Patricia A. Turney | officer: Senior VP, Manufacturing | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
David W Osborne | officer: Chief Technical Officer | |
Kenneth A. Lock | officer: Chief Commercial Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361 |
Matthew Richard Moore | officer: SVP and Chief Business Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361 |
Neha Krishnamohan | director | 12707 HIGH BLUFF DRIVE, SAN DIEGO CA 92130 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Keith R Leonard | director | ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Bhaskar Chaudhuri | director | ONE ENTERPRISE, ALISO VIEJO CA 92656 |
From GuruFocus
By GlobeNewswire • 01-14-2024
By Marketwired • 10-25-2023
By Marketwired • 08-18-2023
By Marketwired • 09-15-2023
By Marketwired • 10-13-2023
By GuruFocus Research • 11-17-2023
By PRNewswire • 12-18-2023
By Marketwired • 10-20-2023
By Marketwired • 08-29-2023
By Marketwired • 10-05-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.